A Phase II Study of BAY 43-9006 [sorafenib] in Relapsed Chronic Lymphocytic Leukemia
Phase of Trial: Phase II
Latest Information Update: 30 Aug 2013
At a glance
- Drugs Sorafenib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 21 Dec 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 15 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.